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One of the most common causes of chronic diarrhea is ascribed to microscopic colitis 
(MC). MC is classified in subtypes: collagenous colitis (CC) and lymphocytic colitis (LC). 
Patients with MC report watery, non-bloody diarrhea of chronic course, abdominal 
pain, weight loss, and fatigue that may impair patient’s health-related quality of life. A 
greater awareness, and concomitantly an increasing number of diagnoses over the last 
years, has demonstrated that the incidence and prevalence of MC are on the rise. To 
date, colonoscopy with histological analysis on multiple biopsies collected along the 
colon represents the unique accepted procedure used to assess the diagnosis of 
active MC and to evaluate the response to medical therapy. Therefore, the emerging 
need for less-invasive procedures that are also rapid, convenient, standardized, and 
reproducible, has encouraged scientists to turn their attention to the identification of 
inflammatory markers and other molecules in blood or feces and within the colonic tissue 
that can confirm a MC diagnosis. This review gives an update on the biomarkers that are 
potentially available for the identification of inflammatory activity, related to CC and LC.
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iNTRODUCTiON
Microscopic colitis (MC) is considered one of the most common causes of chronic, watery diarrhea 
in developed countries. Patients with MC have essentially a normal endoscopic appearance, with 
occasional erythema and/or edema patchy distributed along the colon (1–3). Lymphocytic colitis 
(LC) and collagenous colitis (CC) are the two main histological forms of MC (4). The histopatho-
logical hallmark of LC is a significant lymphocytic infiltration in the surface epithelium, and the 
diagnosis of LC is supported when the intraepithelial lymphocytes exceed 25 per 100 epithelial cells. 
Meanwhile, CC is defined by the presence of a subepithelial collagen band thicker than 10 μm. Both 
CC and LC show an intense infiltration in the lamina propria, mainly of T cells, but there are also 
plasma cells, eosinophils, mast cells, macrophages, and neutrophils (5, 6) (Figure 1) with a normal 
architecture of the crypts (5).
The pathogenesis of MC has yet to be fully clarified (7). Although both immune profiles and 
disease features remain heterogeneous among patients (6–9), CC and LC are currently thought to 
originate from a specific pathological response of the colonic mucosa to several luminal noxious 
agents in predisposed individuals, leading to an inappropriate immune response.
On a clinical point of view, both LC and CC present with very similar symptoms, such as 
chronic or relapsing watery non-bloody diarrhea, most likely of secretory origin. Less frequently, 
FigURe 1 | Histological features of microscopic colitis. Hematoxylin and eosin (A) and anti-CD3 (B) staining in lymphocytic colitis; black arrows indicate 
intraepithelial lymphocyte infiltration. Hematoxylin and eosin (C) and Masson’s Trichrome staining (D) in collagenous colitis; arrows point to the subepithelial collagen 
band. All images also show surface epithelial injury and lamina propria increased cellularity (original magnification: 40×).
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symptoms include cramping, abdominal pain, fecal incontinence, 
and weight loss. Together with the elimination of the chronic 
consumption of drugs, such as simvastatin, lansoprazole, and 
ticlopidine (10–12), budesonide, which is released in the terminal 
ileum and right colon, induces remission within several days. 
Conversely, treatment with immunosuppressive agents has no 
clear effect and relevant number of adverse events (1, 13, 14), even 
if immunosuppressive agents should be effective in patients who 
are corticosteroid-dependent or do not respond to corticosteroid 
treatment (15). Laboratory tests are usually normal or disclose 
unspecific abnormalities.
Previous reports have shown that the fecal biomarkers cur-
rently used to confirm diagnosis and to predict mucosal activity 
in inflammatory bowel diseases (IBDs) [i.e., fecal calprotectin 
(FC)] can be variably increased in some patients with CC (16). 
However, despite being primarily expressed by inflammatory 
cells, such as neutrophilic granulocytes, these biomarkers do not 
reflect the lymphocytic mucosal infiltration and their diagnostic 
accuracy is usually low in patients with MC.
Moreover, from a clinical point of view, there are no features 
that allow clinicians to distinguish between these two conditions 
and the other causes of chronic, watery diarrhea, including func-
tional bowel disorders (17). Therefore, after having ruled out other 
causes of chronic, watery diarrhea with non-invasive laboratory 
tests (e.g., celiac disease, bowel parasitosis, thyroid dysfunction, 
exocrine pancreatic deficiency, and so forth) patients suspected 
for MC are invited to perform a complete colonoscopy, with 
several biopsies throughout the colon. In addition, besides being 
an invasive diagnostic tool, colonoscopy is often carried out to 
reassess the diagnosis in symptomatic patients with a history of 
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MC, as well as to evaluate microscopic healing and response to 
therapy in clinical trials (18, 19).
Recent studies have focused on the need to reduce random 
colonic biopsies in patients with diarrhea, considering some 
characteristic features found in MC patients. Those with MC are 
more than 50  years of age, report weight loss, have a duration 
of diarrhea < 12 months, have recently taken a new drug, and 
have a coexisting autoimmune disease(s) (19). These risk factors 
can help identify those at higher risk of MC and identify those 
who should undergo random colonic biopsies (20). However, the 
sensitivity of these parameters is unacceptably low in terms of the 
potential loss of a MC diagnosis.
For these reasons, there is an emerging need to identify a 
non-invasive diagnostic tool that can predict the presence of 
active MC and distinguish MC from other functional and organic 
causes of watery diarrhea. Such a test would furthermore serve 
to better assess the real need for colonoscopy and histological 
evaluation. Ideally, this non-invasive diagnostic tool should be 
rapid, inexpensive, standardized, reproducible, and accurate in 
reflecting the predominant lymphocytic activity in the large bowel 
of patients suffering from MC.
The aim of this review is to provide an update on the issue of 
diagnostic biomarkers of MC; this overview highlights the emerg-
ing diagnostic tools that should improve our clinical practice in 
the near future.
ePiDeMiOLOgY OF MC
Microscopic colitis is an emerging disease. In fact, the number 
of patients diagnosed with MC has been increasing over the past 
20 years (1). According to epidemiologic studies from Europe and 
US, the prevalence of MC likely ranges from 48 to 219 per 100,000 
person-years (21).
The most recent meta-analysis performed by Tong et  al. 
(22) showed that the overall incidence of CC was 4.14 (95% CI 
2.89–5.40) per 100,000 person-years, while the incidence of LC 
was 4.85 (95% CI 3.45–6.25) per 100,000 person-years at risk.
Geographic variation in the incidence of MC has also been 
observed. The incidence of MC in a recent Danish population-
based study was found to have markedly increased from 4.6 per 
100,000 persons in 2002 to 24.7 per 100,000 persons by the end 
of 2011 (23). Similarly, a population-based study from Olmsted 
County, Minnesota found that incidence of MC increased from 
1.1 per 100,000 persons in the late 1980s to 19.6 per 100,000 
persons by the end of 2001 (24). A further population-based 
study conducted in the same region from 2002 to 2010 confirmed 
the previous trend, showing that the current incidence of MC is 
higher than initially expected, despite that, the growth appears to 
be less pronounced than before (25). The specific incidence of LC 
was 12.0 per 100,000 person-years (95% CI, 9.6–14.3 per 100,000 
person-years) and CC was 9.1 per 100,000 person-years (95% CI, 
7.0–11.1 per 100,000 person-years) (25). Epidemiological studies, 
most of them performed during the last decade, reported mean 
annual incidence rates from 1.8 to 5.4 per 100,000 person-years 
for CC and 1.3 to 4.5 per 100,000 person-years for LC (26–30). 
The causes of geographic variations are still unknown, but they 
probably arise from differences in background populations, 
environmental exposures, health-care systems, referral patterns, 
study designs, or diagnostic criteria.
The causes of the rise in incidence of MC are still a matter 
of debate and a recent study has identified that awareness of 
the disease and changes in the clinical behavior of endoscopists 
and pathologists may be the major drivers (31). It is still unclear 
whether this is just an epiphenomenon of an awareness-detection 
bias or whether this indicates a true increase of disease incidence, 
possibly driven by a wider exposure to some pathogenetic factors 
(e.g., drugs, environmental factors, nutritional factors).
iNCReASeD SeRUM PROTeiNS iN THe 
SeTTiNg OF MC
At the present time, no reliable serum marker has been identified 
in MC. As a matter of fact, even though MC is sometimes asso-
ciated with other immune/inflammatory diseases, it does not 
display prominent signs of systemic inflammatory activation. 
Thus, as previously stated, common serological inflammatory 
markers, such as C-Reactive Protein, are usually normal or only 
slightly elevated in both CC and LC (32) and, as a consequence, 
do not possess any significant role during the diagnostic phase. 
On the other hand, the prevalence of several autoantibodies 
is significantly higher in MC patients compared to controls. 
According to a recent manuscript from Roth et al., in a cohort 
of 133 Swedish women suffering from MC, the prevalence of 
anti-nuclear antibodies, anti-Saccharomyces cerevisiae IgG anti-
bodies, anti-thyroid peroxidase, anti-perinuclear neutrophil 
cytoplasmic antibodies, and anti-glutamic acid decarboxylase 
was 14, 13, 14, 5, and 5%, respectively, with substantially lower 
values in control populations (5, 8, 7, 0, and 0%, respectively). 
In addition, when CC and LC were considered separately, 
the prevalence of these antibodies was greater in LC patients 
compared to CC (32). Another study from Holstein et al. found 
that 15% of patients with CC were positive for ASCA IgA and 
IgG, and 13% of those were also diagnosed with LC. However, 
the difference compared to the control group was statistically 
significant only for patients with CC. Positivity to ASCA 
should be interpreted as a non-specific epiphenomenon that 
should be generated from disturbances of the intestinal bar-
rier (33). Regarding the study of autoantibodies in MC which 
also evaluates the levels of the anti-mitochondrial antibody, 
some research groups showed no variation in the levels of 
these antibodies, which are slightly increased in MC patients 
(34, 35). Despite the great interest of these data, it appears that 
none of the aforementioned antibodies have the potential to be 
used as a serological marker of MC, as they likely possess very 
low specificity and sensitivity, and they are probably linked to 
concomitant autoimmune diseases (32). Serum autoantibodies 
are further summarized in Table 1.
iNCReASeD FeCAL PROTeiNS iN THe 
SeTTiNg OF MC
The identification of sensitive and sufficiently specific biomark-
ers in the feces of patients affected with MC hold promise of 
TABLe 1 | Prevalence of autoantibodies in serum of patients affected by 
microscopic colitis.
Serum marker Setting Prevalence 
(%)
Sample 
size (N)
Reference
Anti-nuclear 
antibodies
CC 10 77 Roth et al. (32)
26 26 Holstein et al. (33)
LC 20 56 Roth et al. (32)
12 16 Holstein et al. (33)
HC 5 100 Roth et al. (32)
5 43 Holstein et al. (33)
Anti-
Saccharomyces 
cerevisiae IgG 
antibodies
CC 9 77 Roth et al. (32)
15 26 Holstein et al. (33)
LC 18 56 Roth et al. (32)
13 16 Holstein et al. (33)
HC 8 50 Roth et al. (32)
0 43 Holstein et al. (33)
Anti-thyroid 
peroxidase
CC 12 77 Roth et al. (32)
LC 16 56 Roth et al. (32)
HC 7 50 Roth et al. (32)
Anti-perinuclear 
neutrophil 
cytoplasmic 
antibodies
CC 5 77 Roth et al. (32)
LC 5 56 Roth et al. (32)
HC 0 50 Roth et al. (32)
1 43 Holstein et al. (33)
Anti-glutamic acid 
decarboxylase
CC 5 77 Roth et al. (32)
LC 5 56 Roth et al. (32)
HC 0 120 Roth et al. (32)
0 43 Holstein et al. (33)
Anti-mitochondrial 
antibodies
CC Not declared 13 Protic et al. (34)
CC 8 38 Bohr et al. (35)
LC Not declared 46 Protic et al. (34)
HC Not declared 18 Protic et al. (34)
5 38 Bohr et al. (35)
LC, lymphocytic colitis; CC, collagenous colitis; HC, healthy control.
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encouraging significant changes in the diagnostic flowchart. 
Indeed, fecal material is easy to collect and testing for fecal 
biomarkers may represent a screening tool before performing 
more invasive examinations, such as colonoscopy. Theoretically, 
in order to be sensitive and specific, fecal markers in MC have 
to recapitulate the most prominent histologic and biochemical 
feature of these diseases, which is the presence of an abundant 
intraepithelial lymphocytic infiltrate. Thus, molecules that ascer-
tain the presence of abundant lymphocytic cellularity and that 
are not degraded within the stools might be promising candidates 
as MC fecal biomarkers. Unfortunately, at the present time, such 
markers do not exist, leaving the need for them completely unmet.
On the other hand, the diagnostic performances of some fecal 
markers of granulocyte activation have been tested in MC, even 
though granulocytes are definitely less prominently represented 
in MC pathology. Indeed, in clinical practice, several molecules 
originating from secreted granules of these cells are already 
widely used in identifying inflammatory conditions of the colon; 
as such, they have also to be tested in MC. Fecal markers are 
further summarized in Table 2.
Fecal Proteins of Neutrophilic Origin
Most of the data available are related to neutrophil granulocyte 
proteins. More specifically, neutrophils can release a multiplic-
ity of toxic oxygen radicals and a variety of granular and soluble 
proteins. Neutrophils play an important defensive role against 
bacteria. Nonetheless, they are also believed to cause mucosal 
tissue injury, leading to the development of several inflammatory 
conditions of the bowel, including MC. The levels of neutrophil-
derived myeloperoxidase (MPO), a lysosomal peroxidase with 
a powerful antimicrobial activity, are usually increased in 
patients with active CC, supporting the role of neutrophils in 
this pathology, and not only in IBD. On the contrary, MPO 
levels in patients with irritable bowel syndrome (IBS) did not 
differ from healthy controls (36, 39). Calprotectin, also known 
as S100A8/S100A9 complex (41), is a calcium-binding protein 
with antibacterial, anti-proliferative, and immunomodulating 
effects. It constitutes two-third of the cytosolic proteins stored 
into neutrophilic granulocytes, even though smaller amounts 
of this protein are also present in macrophages and monocytic 
cells (42). Previous studies have clearly shown that FC levels are 
directly proportional to the neutrophil migration through the 
gut wall and increase with the severity of inflammation (38). 
Consequently, this protein is significantly increased in the feces 
of patients with active inflammatory processes in which neutro-
philic infiltration in the large-bowel mucosal layer is consistent, 
such as in ulcerative colitis (UC) and Crohn’s colitis. Recently, 
the associations between FC and histological inflammation, 
disease activity indices (43, 44), and the ability to predict a 
potential relapse in IBD have been deeply described in UC (45).
Wildt et  al. have clearly showed that FC is significantly 
increased in CC patients as compared to healthy controls, demon-
strating a significant difference between patients with active and 
quiescent disease (16). This evidence confirmed that the mucosal 
inflammatory process in patients with CC is in part due to the 
activation of neutrophils. However, such a pathologic increase 
in FC was not a universal finding; some patients with active CC 
had normal FC and its concentrations may differ considerably 
in patients with active disease (16). More specifically, this study 
showed that out of 21 CC patients with active disease, only 13 
presented with an increased FC (16). To date, it is unclear if this 
difference depends on immunologic responses or on different 
degrees of inflammation. As a matter of fact, both the frequency 
and the entity of FC increase are quite variable, although more 
consistent in UC and also CD—disease conditions in which the 
role of FC is more established.
Lactoferrin is another protein contained in neutrophil 
granules, which is released during active inflammatory condi-
tions (46). Fecal lactoferrin (FL), as is calprotectin, is a marker 
of intestinal inflammation (46). In 1998, Fine et  al. tested the 
increase of FL concentrations in the feces of 103 patients affected 
by chronic diarrhea of unknown etiology and compared it to 10 
healthy control subjects as well as patients with an already known 
intestinal disease (8 Crohn’s disease; 4 UC; 13 celiac disease; 26 
TABLe 2 | Fecal proteins increased in MC.
Cell type Fecal marker Setting Findings and statistics Sample size (N) Reference
Neutrophils Myeloperoxidase CC vs. HC Median 11.7 vs. 2.5 µg/g p < 0.05 18 vs. 20 Lettesjö et al. (36)
CC vs. IBS Median 11.7 vs. 1.7 µg/g p < 0.01 18 vs. 46 Lettesjö et al. (36)
CC vs. HC 10.4 vs. 4.9 µg/g 9 vs. 45 Wagner et al. (37)
LC vs. HC 9.6 vs. 4.9 µg/g 4 vs. 45 Wagner et al. (37)
Calprotectin S100A8/
S100A9
Active CC vs. Quiescent CC Median 80 vs. 26 µg/g p = 0.025 21 vs. 12 Wildt et al. (16)
CC vs. HC Median 80 vs. 6.25 µg/g p = 0.002 21 vs. 13 Wildt et al. (16)
IBD vs. other colitisa vs. IBS Median 349 vs. 92 vs. 49 µg/g p < 0.0001 24 vs. 21 vs. 21 Caviglia et al. (38)
CC vs. HC 74 vs. 61 µg/g 9 vs. 45 Wagner et al. (37)
LC vs. HC 42.7 vs. 61 µg/g 4 vs. 45 Wagner et al. (37)
Lactoferrin Active CC vs. Quiescent CC 1 vs. 0 (no. of positive tests) 21 vs. 12 Wildt et al. (16)
Eosinophils Eosinophil protein X CC vs. HC Median 3.8 vs. 0.46 µg/g p < 0.001 18 vs. 20 Lettesjö et al. (36)
CC vs. IBS Median 3.8 vs. 0.44 µg/g p < 0.001 18 vs. 46 Lettesjö et al. (36)
CC vs. HC 5.7 vs. 0.82 µg/g p = 0.01 9 vs. 46 Wagner et al. (37)
LC vs. HC 1.7 vs. 0.82 µg/g 4 vs. 46 Wagner et al. (37)
Eosinophil cationic protein CC vs. HC 92% of CC > upper limit of normal 12 vs. 44 Wagner et al. (39)
CC vs. HC 5.3 vs. 1.5 µg/g p = 0.01 9 vs. 46 Wagner et al. (37)
LC vs. HC 2.6 vs. 0.82 µg/g 4 vs. 46 Wagner et al. (37)
Mast cells Tryptase CC vs. IBS vs. HC 50 vs. 13 vs. 5.3% detectable levels 18 vs. 46 vs. 19 Lettesjö et al. (36)
Other leukocytes IL-1β CC vs. IBS vs. HC 18% CC detectable levels Undetectable  
in IBS and HC
18 vs. 46 vs. 19 Lettesjö et al. (36)
Tumor necrosis factor α CC vs. IBS vs. HC Undetectable levels 18 vs. 46 vs. 19 Lettesjö et al. (36)
Enteroendocrine 
cells
Chromogranin A CC vs. HC p < 0.001 12 vs. 43 Wagner et al. (40)
CC vs. IBD p < 0.001 12 vs. 32 Wagner et al. (40)
Chromogranin B CC vs. HC p < 0.001 12 vs. 43 Wagner et al. (40)
CC vs. IBD p < 0.001 12 vs. 32 Wagner et al. (40)
Secretoneurin CC vs. HC p < 0.01 12 vs. 43 Wagner et al. (40)
CC vs. IBD p < 0.001 12 vs. 32 Wagner et al. (40)
LC, lymphocytic colitis; CC, collagenous colitis; HC, healthy control; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome.
aOther colitis: microscopic colitis (MC), eosinophilic colitis, and non-specific chronic colitis.
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MC) (47). FL results were normal in all healthy subjects and 
was elevated in all previously diagnosed IBD patients as well 
as in three MC patients. Among the 103 patients with chronic 
diarrhea, 11 presented with increased FL. Patients underwent 
extensive valuation including endoscopic biopsies of the colon 
and small intestine before the final diagnoses for the latter group 
were made and correlated with FL testing results: 10 patients had 
IBD and FL presented with elevated values in 9 of them; 1 patient 
had an ischemic colitis together with high FL; MC was revealed in 
13 patients, but only 1 presented elevated FL. Overall, whereas FL 
was highly accurate in confirming or identifying IBD (90% sen-
sitivity, 98% specificity), only a small percentage of MC patients 
(4 out of 39, 10%) showed positive FL (47). The prevalence of FL 
in CC was also evaluated also in the aforementioned work from 
Wildt et al. (16). In this study, only 1 patient had increased FL 
concentrations in stools, suggesting a very low sensitivity of the 
test in this setting (16).
Overall, it appears that, in a significant proportion of MC 
patients, allegedly those with less severe histologic activity, 
secretory granules proteins are not highly represented in stools; 
therefore, the role of those molecules as markers of MC seems to 
be limited.
Fecal Proteins Produced by eosinophils
Eosinophilic granulocytes are potent pro-inflammatory cells: 
they can induce epithelial damage by releasing several cytotoxic 
granule-derived proteins (48). In addition, they secrete other 
mediators, such as cytokines, chemokines, and leukotrienes, 
which modulate epithelial inflammation (6). In 2001, Levy et al. 
demonstrated that eosinophilic infiltration and degranulation 
were remarkably increased in CC patients’ colonic mucosa as 
compared to healthy controls (49). Consistently, two further 
pilot studies have shown that eosinophil-related inflamma-
tory markers, such as eosinophil cationic protein (ECP) and 
eosinophil protein X (EPX), are significantly increased in fecal 
samples from CC patients as compared to those of IBS patients 
(36, 39). Remarkably, a very recent study tested the diagnostic 
performance of fecal ECP and EPX, together with FC and fecal 
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MPO, in a cohort of 67 patients referred to colonoscopy due to 
chronic non-bloody diarrhea (37). This specific setting is very 
important, since it recapitulates the clinical scenario where the 
availability of MC biomarkers could represent a step forward in 
clinical practice. According to endoscopy and pathology reports 
(available for 63 out of 67 patients), 46 patients were affected 
with IBS; 2 with UC; 2 with CD; 2 with LC; and 9 with CC. 
The results of this study are very promising; in fact, fecal ECP 
and EPX were significantly higher in CC patients and when all 
the four tested fecal markers (ECP, EPX, FC, and MPO) were 
negative, the chances of getting a normal histological description 
were 92%. In addition, in the same study, serum levels of ECP 
and EPX were also measured, without finding any differences 
between the different study groups (37). Indeed, given the small 
number of patients included, these results need to be confirmed 
in larger cohorts, but they still suggest a potential usefulness of 
eosinophil-related inflammatory molecules as markers of MC, 
and more specifically of CC. It is important to keep in mind that 
eosinophils are also indicative of drug-induced inflammation, 
beyond CC and LC (50).
Fecal Proteins from Other Leukocytes
Molecules produced by other types of inflammatory cells have 
been considered, as well. The mast cells are located in the mucosa 
of different organs and tissues and are the main actors in allergic 
reactions. The role of mast cells in inflammatory conditions of the 
gut is not completely understood yet; however, it is known that 
mast cells have an increased propensity to release tryptase in UC 
(51). The presence of this enzyme in fecal matter was also studied 
in CC patients, and detectable levels of fecal tryptase were present 
in about 50% of CC patients, as compared to 13 and 5% of IBS 
patients and healthy controls, respectively (36).
In the same paper, Lettesjö et al. also measured the fecal levels of 
two potent pro-inflammatory molecules, those being interleukin 
1β (IL-1β) and tumor necrosis factor (TNF)-α. These cytokines 
are produced and released primarily by mucosal macrophages 
but also by many different inflammatory and non-inflammatory 
cell types. Indeed, their role and overexpression in active IBD 
is well established (52–56), thus suggesting the rationale to test 
them in MC. Despite this premise, only 18% of patients affected 
by CC presented with enhanced fecal IL-1β levels, while levels in 
the other experimental groups were very low or undetectable, and 
TNF was not detectable in any stool sample (36).
Fecal Proteins from Neuroendocrine Cells
The clinical presentation of MC presents as an increased secre-
tory activity of the bowel and decreased absorption of water and 
electrolytes. The neuroendocrine system of the gut regulates gut 
motility, furthermore guiding water and salts absorption (57–59).
Thus, El-Salhy et  al. hypothesized that in MC there may be 
a hyperactivation/hypertrophy of colonic neuroendocrine cells, 
and consequently, in their study, the authors demonstrated by 
immunohistochemistry an overabundance of Chromogranin A 
(CgA)+ cells interspersed among epithelial cells in LC (no data are 
provided for CC) (60, 61). CgA is part of the granin family and 
a marker for enteroendocrine cells, a protein which is elevated 
in plasma and serum of IBD patients (62). In addition, in most 
neuroendocrine cells, Chromogranin B (CgB) coexists with CgA, 
and it can be used complementary with CgA as an important 
marker for detecting neuroendocrine tumors (63, 64). Also, 
secretoneurin (SN) is a major peptide within the human enteric 
neuroendocrine system (65) and it is a chemoattractant for blood 
eosinophils (66), which also increases spontaneous locomotion of 
neutrophils (67). Therefore, Wagner et al. measured these mol-
ecules in the feces of CC patients and they found that CgA, CgB, 
and SN are detectable in CC patients’ feces and are also markedly 
overexpressed when compared to healthy controls and patients 
with IBD. The considerable differences in the expression of these 
neuropeptides between groups suggest that the enteric nervous 
system is clearly involved in the pathophysiology of CC (40). 
Levels of CgA and CgB are persistently high during treatment in 
CC patients; on the contrary, after therapy, SN levels decrease and 
reach levels found in healthy controls, suggesting an upregula-
tion of the enteroendocrine system (40). In LC patients, CgA has 
never been measured in feces (60). While fecal CgA, CgB, and 
SN are possibly promising markers, studies aimed at evaluating 
prevalence, the best thresholds, sensitivity and specificity in 
predicting MC are strongly needed.
HiSTOLOgiCAL MARKeRS
The diagnosis of MC is mostly based on histological assessment. 
Therefore, several markers have been studied using immunohis-
tochemistry to distinguish between CC and LC and, thus, clarify 
the diagnosis when hematoxylin and eosin staining is not suf-
ficient, as may be the case of “incomplete MC” (iMC). This term 
refers to patients who have the clinical presentation of MC but 
partially fulfill the characteristic histological criteria for the diag-
nosis of LC and CC. In particular, in iMC patients, an increase in 
the number of IELs is observed, but <20/100 epithelial cells in 
superficial epithelium (incomplete LC) and abnormal thickening 
of the subepithelial collagen band <10 µm (incomplete CC). The 
inflammatory infiltrate in the lamina propria is also increased. 
These conditions are classified in literature as borderline LC, 
minimal CC, MC not otherwise specified, and paucicellular LC. 
The term “undefined MC” was chosen to avoid any confusion 
with the iMC term and was introduced with the following defini-
tion: “no information for further subtyping was available.” From a 
strictly histological point of view, however, only the terms CC and 
LC are advisable, and the use of the above-mentioned definitions 
should be avoided when preparing a pathological report (68).
Langner et  al. (5) recently reviewed stainings that are 
commonly used in clinical practice. Anti-CD3 identifies lym-
phocytes, thereby improving the diagnosis of LC. Anti-CD68 
identifies cells belonging to the monocyte/macrophage lineage 
and may be useful in identifying LC and CC with giant cells 
(variants characterized by the presence of multinucleated giant 
cells originating from the fusion of subepithelial macrophages) 
(69–71). Finally, Masson’s trichrome stain highlights the presence 
of the collagen band in CC (5) (Figure 1). Notably, the thick-
ness of the subepithelial collagenous band-like deposit usually 
shows a remarkable variation throughout the colon in CC. In 
addition, routine staining (i.e., hematoxylin and eosin, Masson’s 
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trichrome) do not selectively highlight these deposits (72). The 
solution to this problem would be to label those extracellular 
matrix (ECM) components, which are specifically expressed in 
the subepithelial collagen band.
The abnormal collagen deposition seems to originate from dis-
turbances in the function of subepithelial myofibroblasts, result-
ing in increased synthesis or decreased degradation of ECM (73). 
These cells contribute to the maintenance of the intestinal mucosa 
structure and can synthetize several ECM matrix components 
(73). Tenascins (TNs) are a family of large ECM glycoproteins, 
which are involved in cell adhesion and migration during devel-
opment, tissue homeostasis, and responses to disease or trauma. 
Many TNs can influence the way that fibronectin signals through 
integrins, they have the ability to signal directly through integrin 
receptors or by binding to the ECM glycoprotein fibronectin 
(74). In normal mucosa, in non-specific chronic inflammation, 
and in LC, TNs are weakly expressed; immunostaining detects 
TNs in the majority of cases defined as “not detectable” following 
standard trichrome stains, even though a strong subepithelial 
positive band with lacy appearance and coarse prolongation into 
the lamina propria was observed (73, 75). In CC, a prominent 
extension of the collagen band measuring 12–28 µm was detected 
using TNs immunostaining, resulting in a more accurate meas-
urement of the thickness of the subepithelial collagen deposition 
(76). Immunohistological staining for TNs could be used as a 
routine approach in cases of clinically suspected CC. Other ECM 
components, such as laminin and fibronectin, were not uniformly 
expressed and distributed in the lamina propria of normal and 
inflamed tissues, giving them no value as diagnostic markers of 
MC (73).
Recent studies on fecal stream diversion proposed a 
model in which the collagen deposition is reversible (77, 78). 
Immunohistological findings and in situ hybridization analyses 
on the composition of the immediate pericryptal ECM suggest 
that the pericryptal myofibroblasts express minor amounts of 
collagen type I, III, and VI in the deep parts of the crypts (79). In 
the upper pericryptal area and particularly in the sub-epithelium, 
cells express and deposit increased amounts of type VI collagen 
and initiate TNs synthesis, while some type III collagen is also 
detectable (80). The fact that both proteins accumulate within 
the band-like structures suggests that they represent a pathologi-
cal accumulation of physiological products of the subepithelial 
myofibroblasts (75).
The excessive collagen deposition seems to reflect a local 
disturbance in ECM turnover, resulting in the formation of a 
provisional ECM. Among ECM-degrading enzymes, matrix-
metalloproteinases (MMPs) have a central role. MMPs are a 
family of zinc-dependent neutral proteinases with overlapping 
but distinct substrate spectra. Four subfamilies of MMPs are 
known: collagenases, gelatinases, stromelysins, and membrane-
MMPs (81, 82). Together with MMP-8 (collagenase-2, neutrophil 
collagenase), MMP-1 (collagenase-1, interstitial collagenase) 
and MMP-13 (collagenase-3) form the MMP-subfamily of col-
lagenases, which are instrumental for the degradation of native 
interstitial collagens, in particular collagen type I, II, and III 
(81, 82). Among the abovementioned MMPs, only MMP-1 seems 
to have a role in CC and its expression is increased in subepithelial 
myofibroblasts (83). In any case, MMP-1 expression is counter-
acted by increased tissue of metalloproteinases (TIMP)-1 inhibi-
tor, showing a local impairment in ECM degradation in CC (83).
Vascular endothelial growth factor (VEGF) is a potent pro-
angiogenic molecule, which also increases vascular permeability 
and is overexpressed during growth and metastasis in tumors. 
In chronic inflammatory disorders, it promotes tissue repair and 
plays a central role in ECM degradation (84–86). VEGF limits the 
release of TIMP-1 by endothelial cells, thereby increasing MMP-1 
activity (16, 45). In the epithelium and in inflammatory cells of 
the lamina propria, expression of VEGF reflects an important 
physiological mechanism counteracting the MMP-1/TIMP-1 
imbalance in CC; disinhibiting MMP-1 and reducing levels of 
TIMP-1 leads to an accumulation of immature subepithelial 
ECM in CC (87). An increased immunostaining for VEGF within 
the epithelium is also maintained when clinical and histological 
remission is achieved, suggesting the persistence of the repair 
mechanism (87).
Several studies have been performed on arachidonic acid 
metabolism. The main roles described for prostaglandin (PG) 
in the gastrointestinal tract are related to the enhancement of 
barrier function, wound repair and restitution following damage, 
regulation of mucosal blood flow, and also mucus production and 
secretion.
Prostaglandins are also involved in immune function regula-
tion. A case report (88) demonstrated that a patient with CC 
had extremely high luminal excretion of PGE2 as compared 
to a control subject; PGE2 exerts pro-inflammatory activity by 
upregulating IL-8 in colonic epithelial cells. Another study found 
that PGE2 increases the inflammatory response in the bowel 
through EP4 receptors in dendritic cells (89) and decreases the 
production of inflammatory cytokines in intestinal T cells (90). 
Elevated EP4 receptor levels correlate with high levels of TNF-α 
and could be studied as an ideal biomarker for MC (91).
Cyclooxygenase (COX) is an enzyme involved in PG synthesis 
via the arachidonic acid pathway and is present in two isoenzymes: 
COX-1 and COX-2. The constitutively expressed isoenzyme is 
COX-1, which is believed to be responsible for the production of 
PGs associated with gastrointestinal integrity. Whereas COX-2 
is an inducible isoenzyme, it is rapidly induced by a variety of 
stimuli, such as cytokines, growth factors, hormones, and car-
cinogens, and can also induce the production of PGs contributing 
to inflammation (92). By using western blot analysis, immuno-
histochemistry, and immunofluorescence methods on biopsies 
from patients with CC, the presence and cellular localization of 
COX-2 in colonic mucosa of patients with CC was shown to be 
increased both quantitatively and qualitatively (93). The cellular 
distribution of COX-2 was observed in the inflammatory infil-
trate of the lamina propria, in both plasma cells and particularly 
in the macrophagic subpopulation of the mononuclear cells (93). 
Enhanced expression of COX-2 was shown in the lamina propria 
of biopsies from patients with IBD at intensities similar to CC, 
given this COX-2 should not be useful as a biomarker for MC.
The free radical gas, nitric oxide (NO) is a mediator of inflam-
mation, which may exert secretory actions in the human colon 
(94). In the normal colon, NO is produced from the amino acid 
l-arginin in epithelial cells, endothelial cells, and submucosal 
TABLe 3 | Tissue markers in microscopic colitis (MC).
Tissue marker MC Localization Diagnostic accuracy Sample Size 
(N)
Reference
Chromogranin A LC Higher in left colon 27.2 ± 1.4 cells/mm2 LC vs. 8.9 ± 0.6 
cells/mm2 HC
57 vs. 54 El-Salhy et al. (60)
Tenascins (TNs) CC Subepithelial band 12–28 µm CC vs. 4–6 µm HC 15 vs. 15 Anagnostopoulos et al. (76)
CC Subepithelial band 29.46 ± 1.87 μm CC vs. no TN HC 35 vs. 18 Salas et al. (73)
Type IV collagen CC Deep part of the crypts, penetrating blood 
vessels
CC > 10 labeled cells/mf 12 vs. 7 Günther et al. (83)
Matrix-metalloproteinase-1 CC Subepithelial band CC > 7 labeled cells/mf 12 vs. 7 Günther et al. (83)
Tissue of 
metalloproteinases-1
CC Subepithelial band CC > 10 labeled cells/mf 12 vs. 7 Günther et al. (83)
21 vs. 5 Griga et al. (87)
Vascular endothelial 
growth factor (VEGF)
CC Epithelium 11.61% CC vs. 1.10% HC 21 vs. 5 Griga et al. (87)
VEGF CC Leukocytes in the Lamina propria 0.89% CC vs. 0.04% HC 21 vs. 5 Griga et al. (87)
EP4 receptor CC Intestinal epithelial cells, lymphocytes, and 
lamina propria
expression CC > 10 folds vs. HC 8 vs. 12 Dey et al. (91)
Cyclooxygenase-2 CC Mononuclear cells in the lamina propria Staining ratio 1.93 CC vs. 2.59 HC 10 vs. 8 Wildt et al. (93)
iNOS MC Epithelial cells of the luminal border of crypts OD 8.2 ± 1.5 MC vs. OD 0.8 ± 0.2 HC 12 vs. 6 Perner et al. (100)
LC, lymphocytic colitis; CC, collagenous colitis; HC, healthy control; mf, microscopic field; OD, optical density.
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neuronal cells by constitutive NO synthase (95). In addition, 
normal colonic epithelial cells express the inducible isoform of 
NOS, iNOS, which may contribute to normal mucosal barrier 
function (96). As observed in ulcerative, infectious, collagenous 
or lymphocytic colitis, the generation of NO is highly increased 
(97–99). In biopsy specimens from patients with chronic diarrhea 
and “minimal colitis,” the iNOS antibody was observed only at the 
luminal border in the crypt epithelium, while in healthy volun-
teers it was localized in the epithelial cells of the colon. Western 
blot analysis showed significantly higher iNOS in symptomatic 
patients when compared to healthy volunteers (100). The results 
of these studies suggest that patients with chronic, idiopathic 
diarrhea have an upregulation of iNOS activity in colonic mucosa, 
which results in a severe impairment of fluid absorption in the 
colon.
Taken together, several potential markers for the histopatho-
logical diagnosis of MC do exist, but their capacity in predict-
ing the presence of this disease still needs to be confirmed and 
measured in clinical settings. Indeed, given the high accuracy of 
histologic findings in identifying CC and LC, it is questionable 
whether tissue markers may really improve the ability to diagnose 
MC in clinical practice. As a matter of fact, a possible use of these 
markers may be in those MC cases with incomplete histologic 
or borderline features. In addition, it is worth pointing out that 
some histologic markers may have the potential to limit the 
invasiveness of the endoscopic procedure. In fact, we previously 
mentioned that El-Salhy et al. showed a markedly higher density 
of CgA-expressing cells in LC colonic mucosa, as compared to 
non-MC controls in two studies (61). Interestingly, the second 
study not only confirmed these results but also demonstrated 
that the intense increase of CgA+ cells in LC was consistently 
present both in right and left colonic biopsies (60). As such, the 
authors speculated that, if confirmed, this finding may permit 
to differentiate between a diagnosis of LC and IBS by collecting 
biopsies during a simple sigmoidoscopy, without the need to 
perform a complete colonoscopy. Indeed, this may represent a 
great advantage for patients who have already undergone full 
colonoscopy without tissue sampling during the initial diagnos-
tic work-up or before the onset of diarrhea. Tissue markers are 
further summarized in Table 3.
CONCLUSiON
Over the last few years, growing evidence has shed new light on 
the pathogenesis of MC and has increased physicians’ awareness, 
thus resulting in several concrete improvements in the clinical 
management of these emerging disorders. To date, no reliable 
biomarker of CC and LC is available, and histologic examination 
based on multiple biopsies performed during colonoscopy is 
still the unique tool used to assess the diagnosis in patients with 
suspected MC.
In order to overcome such limitations and to encourage more 
patient-friendly and cost-saving policies, an increasing number 
of studies are amassing a wealth of data on different putative 
serological and fecal tests for MC. Although newly identified 
markers hold some potential, so far, none of the tested molecules 
present sufficient accuracy for use in clinical practice, appearing 
as more useful to study MC pathogenic mechanisms, rather 
than to predict disease activity. In particular, none of the cur-
rently available non-invasive tests allows clinicians to screen and 
monitor patients affected with CC and LC, in order to perform 
endoscopic and pathological evaluations only in selected cases. 
We speculate that, similar to what happens for FC, reflecting 
neutrophil mucosal infiltration in UC, the ideal biomarker for 
MC should mirror CD3+ lymphocyte collection in the mucosal/
epithelial layer, thereby showing high sensitivity and specificity in 
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